Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID-19 mild to moderate meta-analysis

Fu
 
ChiCTR2000030262
RCTinterferon / TFF2standard of careCOVID-19 mild to moderatesome concern
40/40 conclusif
    Jagannathan
     
    NCT04331899
    RCTpeginterferonplaceboCOVID-19 mild to moderatesome concern
    60/60 inconclusive

      PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
      Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).